MGC Pharma operates in several different segments of the Phytocannabinoid-based medicines.
MGC Pharma applies high standards of QA and QC to different segments of the Phytomedicine industry, allowing us to meet and exceed Good Manufacturing Practice (GMP) and GACP protocols, globally. Our company operates three pioneering divisions.
The Pharma Division is focused on our medical product pipeline and is our largest division. This division focuses on products that emerge from our supply line. These include neutraceuticals, which will be able to provide the additional needs and requirements that our body demands on a daily basis to improve our immune system, detoxify and enhance wellness.
Additionally, this includes our extracts, at various levels of purity, and with the ability to extract various phytocannabinoids and terpenes to the level of Active Pharmaceutical Ingredient.
The Innovation division is focused on three specific areas of treatment:
The Botanic Division engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia. We will continue to harvest the product in Slovenia and Czech Republic, and use the raw material at our production facility, as well as provide the product globally.
Our research & development:
MGC Nutraceuticals is our pioneering nutraceutical line for balance and well-being. We are currently working on a new line of nutraceutical products, derived from our pharmaceutical pipeline of MGC Pharmaceuticals.
MGC Nutraceuticals is dedicated to making more premium nutraceutical products, compared to others on the market. All of our products are manufactured in our GMP-certified facility in Slovenia.